CLINICAL EVALUATION OF CEFTRIAXONE (Ro 13-9904) IN THE FIELD OF INTERNAL MEDICINE

• Published in: CHEMOTHERAPY Vol. 32; no. Supplement7; pp. 344 - 350
• Main Authors: ITO, AKIRA, SHINDO, KUNIHIKO, FUKUSHIMA, KOKICHI, KAMINAGA, YOICHIRO, SATO, YOSHIMI, SAKIYAMA, NORIKO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1984
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.32.Supplement7_344

Ceftriaxone (CTRX, Ro 13-9904) is a parenteral cephalosporin developed by F. Hoffmann-La Roche in Switzerland. CTRX has a remarkable antibacterial activity and a broad spectrum against Gram-negative bacteria. CTRX was clinically evaluated as well as about its antibacterial activity in vitro. Bacteria used were 22 strains of E. coli, 22 strains of K. pneumoniae, 24 strains of S. marcescens, 23 strains of P. aeruginosa, 5 strains of P. cepacia and 10 strains of A. calcoaceticus, all clinically isolated. CTRX indicated an MIC value <0.2 μg/ml against all 22 strains of E. coli, an MIC≤.0.4μg/ml against 21 out of 22 strains of K.pneumoniae, an MIC≤0.8 μg/ml against 20 out of 24 strains of S. marcescens, presenting almost an equal activity to CAZ and CZX. Against P. aeruginosa and A. calcoaceticus, the MIC value ranged from 3.1 to 100 μg/ml and from 6.25 to 50 μg/ml, respectively. It suggests no superiority of CTRX to other reference drugs against these types of bacteria. CTRX was administered with 2 g daily by drip infusion into 1 case with bronchiectasia, 1 with septicemia and 2 with cholecystitis; 2 g once a day in 1 case and 1 g twice in 3 other cases. The results were good in all cases. A good response obtained in an out-patient with bronchiectasia, treated only twice a week might be attributed to a long-life in the blood as the characteristic of CTRX. Neither side effects nor laboratory-test abnormalities were found. CTRX could be a useful antibiotic agent if the selection of cases is appropriate.